Last10K.com

Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Amphastar Pharmaceuticals, Inc.

CIK: 1297184 Ticker: AMPH

EXHIBIT 99.1

 

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2018

 

Reports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018

 

RANCHO CUCAMONGA, CA – March 12, 2019  – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31, 2018.

 

Fourth Quarter Highlights

 

·

Net revenues of $89.7 million for the fourth quarter, up 48% from the quarter ended December 31, 2017

·

GAAP net income attributable to Amphastar of $1.9 million, or $0.04 per diluted share, for the fourth quarter

·

Adjusted non-GAAP net income attributable to Amphastar of $6.2 million, or $0.13 per diluted share, for the fourth quarter

 

Full Year Highlights

 

·

Net revenues of $294.7 million for the fiscal year, up 23% from the previous year

·

GAAP net loss attributable to Amphastar of $5.7 million, or $(0.12) per diluted share, for the fiscal year

·

Adjusted non-GAAP net income attributable to Amphastar of $10.4 million, or $0.21 per diluted share, for the fiscal year

 

Dr. Jack Zhang, Amphastar’s CEO, commented: “The fourth quarter ended a great year for our Company. During the quarter we received approval for Primatene® Mist, which followed multiple ANDA approvals and launches throughout the year. Sales grew 48% in the quarter with Primatene® Mist’s launch, and capped off sales growth of 23% for the year.”

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Year Ended

 

 

 

December 31, 

 

December 31, 

 

 

 

2018

 

2017

 

2018

 

2017

 

 

 

(in thousands, except per share data)

 

Net revenues

    

$

89,690

    

$

60,402

    

$

294,666

    

$

240,175

 

GAAP net income (loss) attributable to Amphastar

 

$

1,867

 

$

787

 

$

(5,738)

 

$

3,647

 

Adjusted non-GAAP net income attributable to Amphastar*

 

$

6,231

 

$

4,115

 

$

10,399

 

$

17,334

 

GAAP diluted EPS attributable to Amphastar shareholders

 

$

0.04

 

$

0.02

 

$

(0.12)

 

$

0.08

 

Adjusted non-GAAP diluted EPS attributable to Amphastar shareholders*

 

$

0.13

 

$

0.08

 

$

0.21

 

$

0.36

 


The following information was filed by Amphastar Pharmaceuticals, Inc. (AMPH) on Tuesday, March 12, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amphastar Pharmaceuticals, Inc..

Continue

Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
M & A
Other
Filter Subcategory:
All
Expense
Shares
Product
Earnings
Cash Flow
Income
Debt
Other
Inside Amphastar Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (Loss)
Condensed Consolidated Statements Of Operations
Consolidated Statements Of Stockholders??? Equity
Accounts Payable And Accrued Liabilities
Accounts Payable And Accrued Liabilities (Details)
Accounts Payable And Accrued Liabilities (Tables)
Business Acquisitions
Business Acquisitions (Details)
Commitments And Contingencies
Commitments And Contingencies (Collaboration Agreements) (Details)
Commitments And Contingencies (Operating Lease Agreements) (Details)
Commitments And Contingencies (Purchase Commitments) (Details)
Commitments And Contingencies (Tables)
Customer And Supplier Concentration
Customer And Supplier Concentration (Details)
Customer And Supplier Concentration (Tables)
Debt
Debt (Long-Term Debt Maturities) (Details)
Debt (Narrative) (Details)
Debt (Schedule Of Debt) (Details)
Debt (Tables)
Employee Benefits
Employee Benefits (Details)
Fair Value Measurements
General
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Summary Of Changes In The Carrying Amount Of Goodwill) (Details)
Goodwill And Intangible Assets (Summary Of Expected Amortization Expense) (Details)
Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details)
Goodwill And Intangible Assets (Tables)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Calculation Of Basic And Diluted Net Income (Loss) Per Share) (Details)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Narrative) (Details)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Tables)
Income Taxes
Income Taxes (Narrative) (Details)
Income Taxes (Reconciliation Of The Statutory Federal Income Tax Rate To The Effective Tax Rate) (Details)
Income Taxes (Reconciliation Of Unrecognized Tax Benefits) (Details)
Income Taxes (Schedule Of Deferred Tax Assets/Liabilities) (Details)
Income Taxes (Summary Of Income Before Taxes) (Details)
Income Taxes (Summary Of Provision (Benefit) For Income Taxes) (Details)
Income Taxes (Tables)
Income Taxes (Uncertain Income Tax Positions - Narrative) (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Litigation
Litigation (Details)
Property, Plant, And Equipment
Property, Plant, And Equipment (Narrative) (Details)
Property, Plant, And Equipment (Summary Of Property, Plant, And Equipment) (Details)
Property, Plant, And Equipment (Tables)
Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited) (Details)
Quarterly Financial Data (Unaudited) (Narrative) (Details)
Quarterly Financial Data (Unaudited) (Tables)
Related-Party Transactions
Related-Party Transactions (Details)
Revenue Recognition
Revenue Recognition (Analysis Of Product Return Liability) (Details)
Revenue Recognition (Analysis Of The Chargeback Provision) (Details)
Revenue Recognition (Tables)
Segment Reporting
Segment Reporting (Selected Financial Information By Reporting Segment) (Details)
Segment Reporting (Summary Of Net Revenues By Product Segment) (Details)
Segment Reporting (Summary Of Revenues And Long-Lived Assets By Geographic Region) (Details)
Segment Reporting (Tables)
Stockholders' Equity
Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)
Stockholders' Equity (Common And Preferred Stock) (Details)
Stockholders' Equity (Equity Awards To Consultants And Advisory Board Members) (Details)
Stockholders' Equity (Information Relating To Option Grants And Exercises) (Details)
Stockholders' Equity (Information Relating To Rsu Grants And Deliveries) (Details)
Stockholders' Equity (Key Assumptions Used In Determining Fair Value Of Options Granted) (Details)
Stockholders' Equity (Restricted Stock Units) (Details)
Stockholders' Equity (Share Buyback Program) (Details)
Stockholders' Equity (Share-Based Compensation Expense Included In The Statement Of Operations) (Details)
Stockholders' Equity (Summary Of Nonvested Options) (Details)
Stockholders' Equity (Summary Of Option Activity) (Details)
Stockholders' Equity (Tables)
Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Recent Accounting Pronouncements) (Details)
Summary Of Significant Accounting Policies (Schedule Of Intangible Useful Lives) (Details)
Summary Of Significant Accounting Policies (Schedule Of Pp&Amp;E Useful Lives) (Details)
Summary Of Significant Accounting Policies (Tables)
Ticker: AMPH
CIK: 1297184
Form Type: 10-K Annual Report
Accession Number: 0001297184-19-000013
Submitted to the SEC: Thu Mar 14 2019 4:42:11 PM EST
Accepted by the SEC: Fri Mar 15 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amph/0001297184-19-000013.htm